Frontier Capital Management CO LLC Madrigal Pharmaceuticals, Inc. Transaction History

Frontier Capital Management CO LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $1.34 Million - $2.06 Million	6,591 New	6,591 $1.52 Million
Q4 2020 Jan 19, 2021	SELL	$110.06 - $133.7 $3 Million - $3.65 Million	-27,299 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$99.78 - $124.21 $4.45 Million - $5.54 Million	-44,615 Reduced 62.04%	27,299 $3.24 Million
Q2 2020 Jul 17, 2020	SELL	$60.13 - $125.71 $1.26 Million - $2.64 Million	-20,998 Reduced 22.6%	71,914 $8.14 Million
Q1 2020 Apr 16, 2020	BUY	$66.76 - $93.49 $2.58 Million - $3.62 Million	38,712 Added 71.42%	92,912 $6.2 Million
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $2.76 Million - $3.88 Million	32,718 Added 152.3%	54,200 $4.94 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $505,809 - $638,434	-5,993 Reduced 21.81%	21,482 $1.85 Million
Q2 2019 Aug 14, 2019	SELL	$91.13 - $142.5 $5.49 Million - $8.58 Million	-60,228 Reduced 68.67%	27,475 $2.88 Million
Q1 2019 May 07, 2019	BUY	$103.48 - $143.84 $396,845 - $551,626	3,835 Added 4.57%	87,703 $11 Million
Q4 2018 Jan 25, 2019	BUY	$94.77 - $215.54 $7.95 Million - $18.1 Million	83,868 New	83,868 $9.45 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.9B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.